Avdelningen för immunologi och vaccinlogi
Lista över vetenskapliga publikationer publicerade av forskare på avdelningen för immunologi och vaccinlogi 2002.
1. Ahmed RKS, Mäkitalo B, Karlén K, Nilsson C, Biberfeld G,Thorstensson R. Spontaneous production of RANTES and antigen specific IFN-g production in macaques vaccinated with SHIV-4 correlate with protection against SIVsm challenge. Clin Exp Immunol 129, 11-18, 2002.
2. Andersson J, Liljeström P. & Sönnerborg A. eds. Global HIVTherapeutics – HIV Vaccines. Vaccine vol 20, Special Issue 2002.
3. Bonhoeffer J, Kohl K, Chen R, Duclos O, Heijbel H, Heininger U, Jefferson T, Loupi E and The Brighton: Addressing the Need for Standardized Case Definitions of Adverse Events FollowingImmunization (AEFI). Collaboration.Accepted by Vaccine, August 27, 2002.
4. Brinster C, Chen M, Boucreux D, Paranhos-Baccala G, LiljeströmP, Lemmonier F, Inchauspe G. Hepatitis C virus non-structural protein 3-specific cellular immune responses following single or combined immunization with DNA or recombinant Semliki Forest virusparticles. J. Gen. Virol. 83:369-381, 2002.
5. Chen M, Hu KF, Rozell B, Örvell C, Morein B, Liljeström P. Vaccination with recombinant alphavirus or immune-stimulating complex antigen against respiratory syncytial virus. J. Immunol. 169:3208-3216, 2002.
6. Colmenero P, Chen M, Castaños-Velez E, Liljeström P, Jondal M. Immunotherapy with recombinant SFV-replicons expressing the P815A tumor antigen or IL-12 induces tumor regression, Int. J. Cancer, 98:554-560, 2002.
7. Enbom M, Urassa W, Massambu C, Thorstensson R, Mhalu F, Linde A. Detection of human herpesvirus 8 DNA in serum from blood donors with HHV-8 antibodies indicates possible bloodborne virustransmission. J Med Virol 68, 264-267, 2002.
8. Hallander HO, Paniagua M, Espinoza F, Askelof P, Corrales E, Ringman M, Storsaeter J. Calibrated serological techniques demonstrate signifikant different serum response rates to an oral killed cholera vaccine between Swedish and Nicaraguan children. Vaccine. 2002 Nov 22;21(1-2):138-45.
9. Hanke T, Barnfield C, Wee EGT, Ågren L, Samuel RV, Larke N, Liljeström P. Construction and immunogenicity in a prime-boost regimen of a Semliki Forest virus-vectored experimental HIV clade Avaccine. J. Gen. Virol. 84: 361-368, 2002.
10. Holmgren B, Andersson S, Harding E, van der Loeff MS, Vastrup P, Aaby P, Ariyoshi K, Whittle H. Increased prevalente of HTLV-1 among HIV-2-infected Women but not HIV-2 infected men in rural Guinea-Bissau.
J Acquir Immune Defic Syndr. 2002 jul 1;30(3):342-50.
11. Karlsson GB, Liljeström P. (2002). Delivery and Expression of Heterologous Genes in Mammalian Cells using Self-ReplicatingAlphavirus Vector. In, Methods in Molecular Biology, Gene Delivery toMammalian Cells: Methods and Protocol, in press.
12. Mäkitalo B, Andersson M, Areström I, Karlén K, Villinger F, Ansari A, Paulie S, Thorstensson R, Ahlborg N. ELISpot and ELISA analysis of spontaneous, mitogen-induced and antigen-specific cytokine production in cynomolgus and rhesus macaques. J Immunol Methods 270, 85-97, 2002.
13. Nilsson C, Sutter G, Walther-Jallow L, ten Haaft P, Åkerblom L, Heeney J, Erfle V, Böttiger P, Biberfeld G, Thorstensson R. Immunisation with recombinant modified vaccinia Ankara can modify mucosal SIV infection and delay disease progression in macaques. J Gen Virol 83, 807-818, 2002.
14. Obaro SK, Enwere GC, Deloria M, Jaffar S, Goldblatt D, Brainsby K, Hallander H, McInnes P, Greenwood BM, McAdam KP. Saftey and immunogenicity of pneumococcal conjugate vaccine in combination with diphteria, tetanus toxoid, pertussis and Haemophilus influenzae type b conjugate vaccine. Pediatr Infect Dis J. 2002 Oct;21(10):940-7.
15. Palmowski MJ, Choi EML, Hermans IF, Gilbert S, Chen JL, Gileadi U, Salio M, van Pel A, Man S, Bonin E, Liljeström P, Dunbar PR, Cerundolo V. Competition between CTL narrows the immune response induced by prime-boost vaccination protocols. J. Immunol 168:4391-4398, 2002.
16. The Petra Study team. Biberfeld G co-author. Efficacy of three short-course regimens of zidovudine and lamivudine in preventing early and late transmission of HIV-1 from mother to child in Tanzania, South Africa, and Uganda (Petra study): a randomised, double-blind, placebo-controlled trial. The Lancet 359: 1178-1186, 2002.
17. Thorstensson R, Albert J, Andersson S. Strategies for diagnosis of human T-lymphotropic virus types I and II. Transfusion 42, 780-791, 2002.
18. Stittelaar KJ, Gruters RA, Schutten M, van Baalen CA, van Amerongen G, Cranage M, Liljeström P, Sutter G, Osterhaus ADME. Comparison of the efficacy of early versus late viral proteins in vaccination against SIV. Vaccine 20:2921-2927, 2002.
19. Urassa W, Nozohoor S, Jaffer S, Karama K, Mhalu F, Biberfeld G. Evaluation of an alternative confirmatory strategy for the diagnosis of HIV infection in Dar es Salaam, Tanzania, based on simple rapid assays. J. Virol. Methods 100:115-120, 2002.
20. Weber B, Gürtler L, Thorstensson R, Michl U, Mühlbacher A, Bürgisser P, Villaescusa R, Eiras A, Gabriel C, Stekel H, Tanprasert S, Oota S, Silvestre MJ, Marques C, Ladeira M, Rabenau H, Berger A, Schmitt U, Melchior W. Multicenter evaluation of a new automated fourth-generation HIV screening assay with a sensitive antigen detection module and high specificity. J Clin Microbiol 40, 1938,1946, 2002.
21. Zuber B, Makitalo B, Zuber AK, Wahren B. A novel potent strategy for induction of immunity to HIV-1 reverse transcriptase in primates.
AIDS .2002 Sept 6;16(13):1839-40.
Rapporter
22. Biberfeld G, Buonaguro F, Lindberg A, de Thé G, Yi Z, Zetterström R. Working group report. Prospects of vaccination as a means of preventing mother-to-child transmission of HIV-1. Acta Paediatr 91: 241-243, 2002.
Övriga artiklar
23. Biberfeld G and Lyamuya E. Monitoring immune function. In AIDS in Africa, 2nd Edition. Kluwer Academic/Plenum Publishers, New York, ISBN 0-306-46699-6; 2002: 185-199.
24. Johansen K. MPR-vaccinet orsakar inte autism. Smittskydd 2002 :6:16-17.
25. Olin P, Carlsson RM, Johansen K. Frågor och svar om vaccinationer mot mässling, påssjuka och röda hund. Smittskydd 2002:6:17-24
26. Olin P. Fear of adverse effekts threatens the vaccination programs. Risk of re-emergin of ”old-fashioned” childhood diseases whit the reduced vaccination coverage.
Läkartidningen 2002 Apr 18;99(16):1784-5.
Uppdaterad 2006-05-11 08:57